Physician profile
Margo Block
NPI 1871672287
$164,423.60
in general payments reported to CMS, 2019-2025
26 companies · $935 in 2025
The $935 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $191 · 2021: $316 · 2022: $6,766 · 2023: $35K · 2024: $121K · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $156K · Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $156,332.00 |
| Food and Beverage | $390.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $162,700.67 | 2020-2025 | Pocket Eeg Device, Ceriell Rapid Response Eeg |
| Abbvie INC. | $283.15 | 2021-2023 | Botox |
| Ucb, INC. | $185.66 | 2019-2023 | Nayzilam, Briviact |
| Allergan, INC. | $172.78 | 2019-2021 | |
| Lundbeck LLC | $170.90 | 2019-2023 | Vyepti |
| Amgen INC. | $123.32 | 2021-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $96.59 | 2019-2023 | Austedo |
| Livanova USA, INC. | $84.37 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $82.42 | 2019-2023 | Epidiolex |
| Argenx US, INC. | $60.31 | 2022 | |
| Sk Life Science, INC. | $56.14 | 2021 | |
| Lilly USA, LLC | $52.43 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $44.65 | 2022 | |
| Supernus Pharmaceuticals, INC. | $43.94 | 2019 | |
| Boston Scientific Corporation | $35.48 | 2025 | Watchman Flx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $34.90 | 2022 | |
| Acorda Therapeutics, INC | $28.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.25 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $22.85 | 2019 | |
| Corium, LLC | $21.96 | 2023 | Adlarity |
| Impel Pharmaceuticals INC. | $17.65 | 2023 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $17.06 | 2023 | Rexulti |
| Avion Pharmaceuticals | $15.98 | 2022 | |
| Medtronic USA, INC. | $15.25 | 2020 | |
| Acadia Pharmaceuticals INC | $14.83 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.28 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margo Block listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.